Public Policy and Big Pharma M&A: Prices, Patents and Taxes
This article was originally published in RPM Report
Big Pharma M&A is back in the headlines, though so far the biggest deals have been talked about but not completed. While the business elements of each of the deals are different, there are some common public policy themes.
You may also be interested in...
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.